Phase II Study to Evaluate Conventional Radiation Therapy Followed by Radiosurgical Boost in Clinically Localized Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Radiation: Radiotherapy with IMRT and CyberKnife Boost
- Registration Number
- NCT01618851
- Lead Sponsor
- Georgetown University
- Brief Summary
This phase II study designed to prospectively evaluate the efficacy and morbidity of IMRT with CyberKnife radiosurgical boosts for clinically localized prostate cancer. Patients will be treated with three radiosurgical treatments (6.5 Gy per fraction) followed by IMRT (45 Gy in 25 fractions).
- Detailed Description
This is a phase II study designed to prospectively evaluate the efficacy and morbidity of IMRT with CyberKnife radiosurgical boosts for clinically localized prostate cancer. Patients with clinically localized prostate cancer will be treated with three radiosurgical treatments (6.5 Gy per fraction to the PTV) followed by IMRT (45 Gy in 25 fractions). Treatment will be completed over a 6-7 week period.
The hypothesis is that for patients with clinically localized adenocarcinoma of the prostate, CyberKnife Radiosurgery delivered to the prostate is efficacious with acceptable toxicity in combination with IMRT.
Subjects will have toxicity evaluation and AUA score on the last day of treatment. At 1 month following treatment, subjects will be assessed for acute toxicity and will fill out AUA form, SF-12, EPIC-26, SHIM and Utilization of Sexual Rx/Devices. At 3, 6, 12, 18 and 24 month intervals (and every 6 months thereafter, through year 5, and annually through year 10, if investigators opt to continue past year 5), subjects will be seen and evaluated, including a history, physical exam, performance status, PSA, toxicity evaluation, and AUA score. In addition, at 6 months, 12 months and annually thereafter, the SF-12, EPIC-26, SHIM and Utilization of Sexual Medications/Devices will be administered. A prostate biopsy will be performed at time of biochemical or local clinical failure, and is encouraged at 2 years following treatment and at time of distant failure. A bone scan will be performed at the time of biochemical failure, or when the subject develops signs of symptoms suggesting metastatic disease.
Acute side effects (≤ 90 days of treatment start) will be assessed using the NCI Toxicity Criteria version 3.0.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- Male
- Target Recruitment
- 70
- Histologically confirmed adenocarcinoma of the prostate (Biopsy within one year of enrollment)
- Signed Study-Specific COnsent
- PSA within 60 days of registration
- Baseline AUA score is less than 20
- Prior Pelvic radiotherapy
- Prior Radical Prostate surgery
- Recent (within 5 years) or concurrent cancers other than non-melanoma skin cancer
- Medical or psychiatric illness that would interfere with treatment or follow-up
- Implanted hardware adjacent to the prostate that would prohibit appropriate treatment planning and/or treatment delivery.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description IMRT with SBRT Boost Radiotherapy with IMRT and CyberKnife Boost Patients with clinically localized prostate cancer will be treated with three radiosurgical treatments (6.5 Gy per fraction to PTV) followed by IMRT (45 Gy in 25 fractions) over 6-7 weeks.
- Primary Outcome Measures
Name Time Method Local failure 2 years after radiotherapy. To estimate the rate of local failure as assessed by 2 year post-radiotherapy prostate biopsies. (Studies with the CyberKnife radiosurgery would be worthwhile for prostate cancer patients if the rate of local control was \> 70%)
- Secondary Outcome Measures
Name Time Method Patient Reported Quality of Life: Expanded Prostate Cancer Index Composite-26 (EPIC-26) During the 5 years following radiotherapy Expanded Prostate Cancer Index Composite-26 contains 26 questions assessing: Urinary Incontinence, Urinary Irritative/Obstructive, Bowel, Sexual, and Hormonal therapy. Response range 0-4 (0 =no problem, 4=big problem).
Patient Reported Quality of Life: Sexual Health Inventory for Men (SHIM) During the 5 years following radiotherapy Sexual Health Inventor for Men Sexual health classifies severity of erectile dysfunction with the following breakpoints: 1-7 Severe ED 8-11 Moderate ED 12-16 Mild to Moderate ED 17-21 Mild ED
Biochemical disease-free survival (bDFS) 2 years after radiotherapy To assess secondary efficacy endpoints: Biochemical disease-free survival (bDFS) assessed using both Phoenix and ASTRO definitions, disease-free survival, disease-specific survival, time to failure, overall survival, duration of local control, and proportion of distant failure at 2 years.
Patient Reported Quality of Life: American Urological Association symptom index During the 5 years following radiotherapy American Urological Association (AUA) symptom index to assess bothersome urinary symptoms on a scale of 0-5 (0 = not at all, 5 = almost always) for assessment. Numbers are tallied and total score of 1-7 MILD, 8-19 MODERATE, 20-35 SEVERE. Patient reported quality of life is recorded as; 0-6 (0=no symptoms, 6=extremely unhappy).
Gastrointestinal and genitourinary toxicity During 5 years following the CyberKnife SRS treatment for prostate cancer To estimate the proportion of patients who develop late grade 3-5 gastrointestinal and genitourinary toxicity observed during the five years following CyberKnife SRS for prostate cancer.
Patient Reported Quality of Life: Utilization of Sexual Medications and Devices During the 5 years following radiotherapy Utilization of Sexual Medications/Devices is optional and assesses the use of erectile aids by patients treated for prostate cancer.